HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, Ch… Read more
HOB Biotech Group Corp Ltd (688656) - Total Liabilities
Latest total liabilities as of September 2025: CN¥136.22 Million CNY
Based on the latest financial reports, HOB Biotech Group Corp Ltd (688656) has total liabilities worth CN¥136.22 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HOB Biotech Group Corp Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how HOB Biotech Group Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HOB Biotech Group Corp Ltd Competitors by Total Liabilities
The table below lists competitors of HOB Biotech Group Corp Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu LiXing General Steel Ball Co Ltd
SHE:300421
|
China | CN¥697.50 Million |
|
Shenzhen Das Intellitech Co Ltd
SHE:002421
|
China | CN¥4.48 Billion |
|
Toyo Ink SC Holdings Co. Ltd
F:TO5
|
Germany | €182.50 Billion |
|
Taiheiyo Cement Corp
PINK:THYCY
|
USA | $754.73 Billion |
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
USA | $6.15 Billion |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658
|
China | CN¥1.80 Billion |
|
Investors Real Estate Trust
F:WXC1
|
Germany | €1.21 Billion |
|
Guangzhou Wondfo Biotech Co Ltd
SHE:300482
|
China | CN¥1.09 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down HOB Biotech Group Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HOB Biotech Group Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HOB Biotech Group Corp Ltd (2016–2024)
The table below shows the annual total liabilities of HOB Biotech Group Corp Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥220.67 Million | +59.30% |
| 2023-12-31 | CN¥138.52 Million | -16.04% |
| 2022-12-31 | CN¥164.99 Million | +75.67% |
| 2021-12-31 | CN¥93.92 Million | +4.33% |
| 2020-12-31 | CN¥90.02 Million | -32.59% |
| 2019-12-31 | CN¥133.54 Million | +44.99% |
| 2018-12-31 | CN¥92.10 Million | +41.27% |
| 2017-12-31 | CN¥65.20 Million | -4.04% |
| 2016-12-31 | CN¥67.94 Million | -- |